Use of insulin glargine throughout pregnancy in 102 women with type 1 diabetes.
OBJECTIVE
The aim of this study was to examine the safety of insulin glargine during pregnancy in women with type 1 diabetes mellitus (T1DM).


METHODS
This retrospective multicentre study involved women with T1DM treated with insulin glargine before conception and throughout pregnancy. The main investigated parameters were HbA(1c) during the first and third trimesters, major congenital malformations, and perinatal mortality and complications.


RESULTS
For the 102 women with T1DM in the study, HbA(1c) during the first and third trimesters was 6.7+/-1.2% (95% CI 6.4-6.9%) and 6.2+/-0.9% (95% CI 6.0-6.4%), respectively. Two congenital malformations (2%) were reported, and one stillbirth (1%) occurred at week 35 of gestation. The rate of preterm delivery was 23%. The mean birth weight was 3381+/-595 g (95% CI 3255-3506 g), and the proportion of large-for-gestational-age infants was 30%.


CONCLUSIONS
Insulin glargine use throughout pregnancy does not appear to be associated with an increased rate of severe congenital malformations.
Lepercq
J
J
Service de gynécologie-obstétrique, hôpital Cochin-Saint-Vincent-de-Paul, AP-HP, 82, avenue Denfert-Rochereau, 75674 Paris cedex 14, France. j.lepercq@svp.aphp.fr
Jacqueminet
S
S
Hieronimus
S
S
Timsit
J
J
Grimaldi
A
A
D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D011247:Pregnancy; D011256:Pregnancy Outcome; D011254:Pregnancy in Diabetics / Q000188:drug therapy*; D012189:Retrospective Studies
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine